

cResponse Report

PATIENT DETAILS

Patient Name	Ordering Physician
Patient ID	Contact Details
Gender	Medical Center
Report Date	Cancer Type

SPECIMEN DETAILS


Sample ID	Date of Sample Received
Date of Biopsy	Biopsy Site

SPECIMEN MEETS QUALITY CRITERIA FOR cRESPONSE TEST

Yes

No

TEST RESULTS



cResponse Report

cRESPONSE SCORE

TREATMENT	SCORE
Doxorubicin	82
Alpelisib	68
Temodal+Olaparib	37
Gemzar+Docetaxel	32
Pazopanib	24
Ifosfamide	16
Palbociclib	0
Olaparib	45

Scoring represents the response to treatment shown by the sample in EVOC. Scoring is based on morphological and histological analysis computed into a predictive algorithm. Score < 30 is considered as no response. For a detailed description of the assay refer to page 4.

DRUGS ADDED BASED ON GENOMIC FINDINGS

GENE	ALTERATION	TESTED DRUG
PIK3CA	c.3140A>G	Alpelisib

Full Genomic report in Appendix A









SUMMARY

5 pieces of core needle biopsy arrived. Histological evaluation upon arrival had high percentage of neoplastic cells therefor meets the criteria for cResponse functional assay as well as NGS assay.

The tissue had strong response to Doxorubicin, moderate response to Alpelisib, which was added to the functional assay based on the NGS analysis, and weak response to Gemcitabine+Docetaxel, Olaparib and Temodal+Olaparib. No effect on the tissue was observed when treated with Ifosfamide, Pazopanib and Palbociclib.

cResponse Report

HISTOLOGY

Control	Ifosfamide	Gemzar+Docetaxel	Doxorubicin	
				H&E
				Ki67

Pathologist: _____ / _____

(first name, last name)

(signature)

cResponse Report

cRESPONSE ASSAY

Tumor sections are cultured for 5 days with selected drugs and then fixed and processed to generate sections stained with morphological and histological markers. The viability of the cancer cells as well as their morphology (assessed by number of parameters such as nuclear details, cohesiveness of the tissue, cytoplasmic changes and others) are analyzed with a proprietary evaluation algorithm to generate the cResponse score. Higher scores correlate to improved clinical response. For more information on the method, see: Ben-Hamo R, Jacob Berger A, Gavert N, et al. Predicting and affecting response to cancer therapy based on pathway-level biomarkers. *Nat Commun.* 2020;11(1):3296. Published 2020 Jul 3. doi:10.1038/s41467-020-17090-y

PUBLICATIONS

1. Grinshpun A, Gavert N, Granit RZ, et al. Ev vivo organ culture as potential prioritization tool for breast cancer targeted therapy. *Cancer Biol Ther.* 2018;19(8):645-648. doi:10.1080/15384047.2018.1450114
2. Ben-Hamo R, Jacob Berger A, Gavert N, et al. Predicting and affecting response to cancer therapy based on pathway-level biomarkers. *Nat Commun.* 2020;11(1):3296. Published 2020 Jul 3. doi:10.1038/s41467-020-17090-y
3. Nejman D, Livyatan I, Fuks G, et al. The human tumor microbiome is composed of tumor type-specific intracellular bacteria. *Science.* 2020;368(6494):973-980. doi:10.1126/science.aay9189
4. Salpeter S, Stossel C, Bar B, Aharon S, Torovsky L, Zundelevich A, Shahar H, Shapira H, Mallel G, Gavert N, Straussman R, Golan S, Rosenbaum E, Dotan Z, Berger R, Leibovici L, Breuer S, Rottenberg Y, Hubert A, Nechushtan H, Zick A, Neev G, Gola T. A clinical trial of cResponse, a functional assay for cancer precision medicine. *AACR* 2021.

DISCLAIMERS

cResponse is a drug prioritization tool (the “Tool”) provided by Curesponse Ltd (the “Company”). The Tool is intended for use by qualified healthcare professionals for informational purposes only. The results report generated by the Tool (the “Report”) does not constitute a clinical diagnosis report, medical advice, diagnosis or medical recommendation, and does not serve as a substitute for the professional advice of a qualified healthcare professional.

This Report should not be the sole input for diagnosis, prognosis, or as the primary basis of making therapeutic decisions, medical history should always be considered when making any treatment decisions, and the experience and clinical judgment of the treating physician should ultimately determine which treatment is selected.



The Company does not endorse warranty or guarantee the effectiveness of any specific course of action, resources, tests, physician or other health care providers, drugs, biologics, medical devices or other products, procedures, opinions, or other information that may be mentioned on the Report. The Company makes no promise or guarantee that a particular drug referenced in the Report will be effective in the treatment of a disease in any patient or the effects such drug may have on the patient.

The use of the Tool is subject to the Company’s Terms of Sale.

Appendix A – Full NGS report


cResponse Report

APPENDIX 1

Test Name	H&E
Imm control	
Ifosfamide	

cResponse Report

A

Test Name	H&E
Gemzar+Docetaxel	
Doxorubicin	